**A modified oral sugar test for evaluation of insulin and glucose dynamics in horses**

Sanna Lindåse*, Katarina Nostell and Johan Bröjer

*From Animal Obesity – causes, consequences and comparative aspects
Uppsala, Sweden. 14–16 June 2015*

**Abstract**

**Background:** An oral sugar test (OST) using Karo® Light Corn Syrup has been developed in the USA as a field test for the assessment of insulin dysregulation in horses but the syrup is not available in Scandinavian grocery stores. The aim of the study was to compare the results of a modified OST between horses with equine metabolic syndrome (EMS) and healthy horses using a Scandinavian commercially available glucose syrup (Dansukker glykossirap). In addition, the effect of breed and the repeatability of the test were evaluated. In the present study, clinically healthy horses (7 Shetland ponies, 8 Icelandic horses, 8 Standardbred horses) and 20 horses of various breeds with EMS underwent the modified OST test. The Icelandic horses and Shetland ponies underwent the OST twice. Insulin and glucose data from the OST were used to calculate peak insulin concentration (PeakINS), time to peak insulin concentration (T-peakINS), area under the curve for insulin (AUCINS) and glucose (AUCGLU) as well as whole body insulin sensitivity index (ISICOMP).

**Results:** Compared to the healthy group, the EMS group had 6–7 times higher geometric mean for PeakINS and AUCINS and 8 times lower geometric mean for ISICOMP. The EMS group had a delayed T-peakINS compared to the healthy group. There was no effect of breed in the group of healthy horses on PeakINS, T-peakINS, AUCINS, AUCGLU and ISICOMP. Coefficient of variation for repeated tests was 19.8, 19.0 and 17.6 % for PeakINS, AUCINS and ISICOMP respectively.

**Conclusions:** The results of the present study demonstrate that the modified OST appears to be a practical and useful diagnostic tool for assessment of insulin dysregulation in the horse. However, to make it possible to establish the most appropriate sampling interval and to evaluate the accuracy of the modified OST, further studies in horses with a variable degree of insulin resistance are needed, where results from the modified OST are compared with quantitative measurements for IS.

**Keywords:** Horse, Insulin dysregulation, Insulin resistance, Oral sugar test

---

**Background**

Equine metabolic syndrome (EMS) refers to a group of clinical abnormalities including generalized obesity and/or regional adiposity, insulin resistance (IR) and hyperinsulinemia [1]. Postprandial hyperinsulinemia is a risk factor for development of laminitis [2–7], and since EMS is a rising concern in the equine population worldwide, it is important to create appropriate diagnostic tests for abnormalities in insulin regulation. In humans, glucose and insulin data from an oral glucose tolerance test (OGTT) can be used to calculate surrogate estimates for insulin sensitivity (IS) that are well correlated to IS quantified by the euglycemic hyperinsulinemic clamp (EHC) [8–10]. The composite whole-body insulin sensitivity index (ISICOMP), also called the Matsuda index, is a commonly used OGTT-derived estimate for IS in humans [10]. The use of ISICOMP as an estimate for IS in the horse has recently been evaluated against quantitative measurements of IS [11]. Despite these relationships OGTT does
not measure IS per se. Instead, it is a test in which both glucose disposal and insulin secretion are stimulated but the test is influenced by factors such as gastric emptying, degree of hepatic glucose trapping, β-cell responsiveness and incretin effects [12].

Due to the association between hyperinsulinemia and laminitis in the horse [13], identification of individuals with an exaggerated postprandial insulin response using OGTT may enable better management of horses and ponies at risk for pasture-associated laminitis. An alternative to the OGTT, where glucose is used as the only carbohydrate source, is the recently developed oral sugar test (OST) [14]. This test uses a standardized amount of Karo® light corn syrup, which is composed of different unknown carbohydrates. Karo® light corn syrup is, however, not available in Scandinavian grocery stores. The aim of the present study was therefore to compare the results of a modified oral sugar test (OST), using a Scandinavian commercially available glucose syrup (Dansukker glykossirap), in a group of healthy horses and in horses with EMS. In addition, the effect of breed on the test result and the repeatability of the test were studied in clinically healthy horses.

Methods

Horses

The study was approved by the Ethical Committee for Animal Experiments, Uppsala, Sweden. Twenty-three clinically healthy horses and 20 horses with EMS were included in the study. The clinically healthy horses were seven Shetland ponies, eight Icelandic horses and eight Standardbred horses. Inclusion criteria for these horses were a body condition score (BCS) of ≤6.5 (scale 1–9) [15], a cresty neck score (CNS) of ≤3.0 (scale 0–5) [16], normal findings on clinical examination, no history of laminitis based on veterinary information and a normal plasma ACTH. The Icelandic horses were used for leisure riding whereas the Standardbred horses and Shetland ponies were sedentary horses. The horses with EMS were two Fjord horses, one Swedish warmblood, ten Icelandic horses, two Shetland ponies, one Welsh Cob, one Highland pony, one Swedish riding pony, one crossbreed horse and one crossbreed pony. The horses with EMS were recruited from a group of horses referred for an extended evaluation of EMS at the University Animal hospital, Swedish University of Agricultural Sciences. Criteria for inclusion were IR, defined as a M/I ratio of ≤3.5 calculated from an EHC, and a normal plasma ACTH. In addition, horses had to have either ≥1 previous episode of laminitis not associated with other predisposing conditions or a CNS >3 [16]. Also, horses eligible to participate had no significant findings on clinical examination, were fed a roughage based diet without grain supplementation and had no ongoing episode of laminitis. Physical characteristics for the two groups of horses are reported in Table 1. All horses were privately owned except for the clinically healthy Standardbred horses, which belonged to the Swedish University of Agricultural Sciences research herd. All horses in the study were fed a hay or haylage diet supplemented with minerals and six of the Icelandic horses were feed 50–100 g of grain 3–5 times/week as a treat. Horses were housed in individual box stalls and allowed daily turnout in a dirt or a sand paddock. None of the horses had been at grass pasture for at least 2 month prior to testing.

Experimental design

The healthy horses were examined in their home environment whereas the horses diagnosed with EMS were examined at the large animal clinic at the Swedish University of Agricultural Sciences after an acclimatization period of 2 days. All horses in the study were examined once with the modified OST. The Icelandic horses and Shetland ponies in the healthy group were examined twice with 8 days in between, to assess the repeatability of the OST. Horses in the EMS group were tested with an EHC 24 h after the OST. Both the OST and the EHC commenced after 12 h of feed withdrawal overnight but with free access to water.

Table 1 Baseline physical characteristics of horses in healthy (n = 23) and equine metabolic syndrome (EMS) (n = 20) groups

| Group                  | Age (years) | Body weight (kg) | Body condition score (1–9) | Cresty neck score (0–5) |
|------------------------|-------------|------------------|---------------------------|------------------------|
| EMS (n = 20)           | 13.9 ± 4.6 (5–22) | 395 ± 117 (124–558) | 6.9 ± 1.1 (5.5–9.0)       | 3.7 ± 0.6 (2.5–5.0)     |
| Healthy (n = 23)       |             |                  |                           |                        |
| Shetland pony (n = 7)  | 3.9 ± 2.7 (1–9)  | 152 ± 29 (115–194) | 5.6 ± 0.6 (5.0–6.5)       | 2.6 ± 0.4 (2.0–3.0)     |
| Icelandic horse (n = 8)| 7.0 ± 2.0 (5–10)  | 342 ± 21 (296–360) | 6.0 ± 0.4 (5.5–6.5)       | 2.6 ± 0.2 (2.5–3.0)     |
| Standardbred horses (n = 8)| 10.5 ± 4.7 (5–20) | 507 ± 56 (441–595) | 5.0 ± 0.3 (4.5–5.5)       | 2.0 ± 0.5 (1.5–2.5)     |

Data are presented as mean ± standard deviation (SD) (range)

Means with different superscript letters within column differ at P < 0.02
OST—oral sugar test
The day before the OST an intravenous catheter (Intraneule, 2.0 × 105 mm, Vygon, Ecouen, France) was inserted aseptically into one of the jugular veins under local anesthesia (EMLA, Astrazenica AB, Södertälje, Sweden). On the morning of the OST, Dan Sukker Glykosirip (Nordic Sugar A/S, Copenhagen, Denmark) was syringed per os at a dosage of 0.2 ml/kg body weight, providing 216 mg/kg BW of saccharides (Table 2). Blood samples were collected from the jugular catheter into evacuated tubes (Vacuette 9 ml, Greiner Bio-One GmbH, Kremsmünster, Austria) containing lithium heparin, immediately before (−5 min), and at 30, 60, 90, 120, 150 and 180 min after the oral administration of syrup. After collection of each blood sample the catheter line was immediately flushed with 10 ml 0.9 % sterile saline solution. Sample tubes were centrifuged for 10 min at 2700 × g and plasma was subsequently harvested and stored at −80 °C until analysis of plasma glucose and plasma insulin.

Insulin and glucose data from the OST were used to calculate the following variables: Peak insulin concentration (PeakINS), time to peak insulin concentration (T-peakINS), area under the curve for insulin (AUCINS), area under the curve for glucose (AUCGLU) and composite whole-body insulin sensitivity index (ISICOMP) [10]. AUCINS and AUCGLU were calculated by use of the trapezoid method (GraphPad Prism, version 6.0 for windows; GraphPad Software Inc, San Diego, CA). ISICOMP was calculated by the following formula: $1000/\sqrt{(G \cdot I) \cdot (MG \cdot MI)}$, where G = baseline glucose concentration, I = baseline insulin concentration, MG = mean glucose concentration during the OST and MI = mean insulin concentration during the OST. A numerator of 1000 was used in the formula, to transform the data into manageable values.

EHC—euglycemic hyperinsulinemic clamp
For horses in the EMS group, a second intravenous catheter (Intraneule, 2.0 × 105 mm, Vygon, Ecouen, France) was inserted into the contralateral jugular vein after the OST examination. On the morning of the following day blood samples for the determination of baseline concentrations of plasma glucose and plasma insulin were drawn from one of the intravenous catheters immediately before (−10, −5, and −1 min) the start of the EHC.

The EHC technique has previously been described for use in horses [17, 18]. Briefly, a continuous rate infusion of glucose (Glucose Fresenius Kab 500 mg/ml, Fresenius Kab AB, Upplands, Sweden) and recombinant human insulin (Humulin Regular, Eli Lilly Sweden AB, Solna, Sweden) was initiated through one of the jugular catheters, using a multi-channel volumetric infusion pump (Colleague, Volumetric infusion pump, Baxter Healthcare SA, Zurich, Switzerland). The infusion rate for insulin was constant at 3 μU/kg/min and a variable rate of glucose was infused to maintain blood glucose concentration at euglycemia (5 mmol/L) during the 3 h long infusion. The glucose infusion rate was adjusted if the concentration deviated by more than 0.2 mmol/L from euglycemia. Blood samples were obtained every 5 min for analysis of blood glucose using a handheld glucometer (Accu-Check Aviva, Roche Diagnostics Scandinavia AB, Bromma, Sweden) and every 10 min throughout the EHC for subsequent determination of plasma glucose (10 min intervals) and plasma insulin (20 min intervals). After collection of each blood sample, the catheter line was immediately flushed with 10 ml 0.9 % sterile saline solution.

The first 120 min of the EHC were considered an equilibration period. Glucose and insulin data from the final 60 min (steady-state) were used for calculation of insulin sensitivity (M/I ratio). The M/I ratio was calculated for each 20-min interval where M is the mean glucose infusion rate and I is the plasma insulin concentration for the interval. The M/I60 is the mean of the three M/I ratios during steady state [17].

Analysis of blood samples
Plasma glucose concentrations were measured enzymatically with an automated clinical chemistry analyzer (YSI 2300 Stat Plus Analyzer, YSI Incorporated, Yellow Spring, Ohio). Endogenous equine plasma insulin concentrations from the OST were determined using a commercial equine-optimized ELISA (Mercodia Equine Insulin ELISA, Mercodia AB, Uppsala, Sweden) evaluated for use in horses [19] and insulin levels were controlled with a commercial kit (Mercodia Animal Insulin Control (Low, Medium, High), Mercodia AB, Uppsala, Sweden). Plasma insulin concentrations from the continuous rate infusion of recombinant human insulin during the EHC procedures were determined using a commercial human ELISA (Mercodia Insulin ELISA, Mercodia AB, Uppsala, Sweden) and a commercial kit (Mercodia Diabetes Antigen Control (Low, High)/Human, Mercodia AB, Uppsala, Sweden) was used as a control. All analyses of plasma glucose and insulin were performed in duplicate. The mean intra-assay CVs for glucose, equine insulin (equine-optimized ELISA) and human insulin (human ELISA)

**Table 2** Chemical composition of the Dan Sukker Glykosirap

| Dry matter (%) | Glucose (%) | Maltose (%) | Maltotriose (%) | Other sugars (%) | Density (20 °C) |
|----------------|------------|-------------|----------------|-----------------|---------------|
| 77             | 12         | 11          | 10             | 44              | 1.40 kg/L     |

Product specification | PS 236654-1.3EN. Nordic Sugar A/S, Copenhagen, Denmark
were 0.4, 2.7 and 2.7 % respectively, as determined from duplicate analyses.

**Statistical analysis**

All data were analyzed in JMP Pro 11.0.0. (SAS Institute Inc., Cary, North Carolina, USA). Differences in plasma glucose and insulin concentrations for the healthy and the EMS groups were compared at different time points during the OST, by use of a 2-way ANOVA for repeated measures. Differences in physical characteristics (age, BCS, CNS and body weight) and OST derived calculated variables (AUCGLU, AUCINS, ISICOMP, PeakINS and T-peakINS) were compared between breeds and between the healthy and EMS groups by use of an independent t test or a 1-way ANOVA as appropriate. Differences in calculated variables for repeated OST tests were compared by use of a paired t test. The repeatability of the OST was determined by the mean coefficient of variation (mean CV), the intraclass correlation coefficient (ICC) and the repeatability coefficient (RC). The ICC was calculated according to the formula $1 - S_{sb}^2/(S_{sb}^2 + S_{sw}^2)$ and the RC was calculated as $2.77S_{sw}$, where $S_{sw}$ is the within subject variance and $S_{sb}$ is the between subject variance calculated from the analysis of variance table of a 1-way ANOVA [20]. Values of $P < 0.05$ were considered as significant for all analyses. If residuals were not normally distributed data were logaritmithcally transformed. Logaritmithcally transformed data were then expressed as the geometric mean ± 95 % CI on the original scale after back transformation. All other results were expressed as mean ± SD, whereas data for age, body weight, BCS and CNS were additionally presented with the range.

**Results**

All horses included in the study fulfilled the inclusion criteria for the separate groups. All horses tolerated the administration of syrup well. The loss of syrup was negligible comprising the small amount that got stuck to the outside of the syringe during administration.

**Comparison of EMS and healthy horses**

All horses in the EMS group were defined as insulin resistant by a M/I60 of <3.5 (μg/kg/min)/(mU/L). Fourteen of 20 included horses with EMS had a severe IR i.e. M/I60 < 2.0 (μg/kg/min)/(mU/L). Sixteen of the 20 horses included in the EMS group had previous episodes of laminitis. The EMS group had a higher mean CNS compared to the breeds included in the healthy group ($P < 0.0004$). Mean BCS was higher in the EMS group compared to the Standardbred horses and Shetland ponies of the healthy group ($P < 0.010$), but no difference was found between the EMS group and the healthy Icelandic horses ($P = 0.074$) (Table 1).

There was an overall effect of time between the group of healthy horses and EMS horses during the OST for insulin ($P < 0.0001$) but not for glucose ($P = 0.178$). An overall interaction between group of horses (clinically healthy vs EMS) and time was identified for both insulin ($P < 0.0001$) and glucose ($P = 0.003$) (Fig. 1).

Compared to the healthy group, the EMS group had 6–7 times higher geometric mean for PeakINS ($P < 0.0001$) and AUCINS ($P < 0.0001$) and 8 times lower geometric mean for ISICOMP ($P < 0.0001$) (Fig. 2). Horses in the healthy group reached the maximum insulin concentration (T-peakINS) on average 69 ± 27 min from the start of the OST. Horses in the EMS group reached the maximum insulin concentration (T-peakINS) on average 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively. For the EMS group the geometric means (95 % CI) for insulin were found in the EMS group compared to the healthy group ($P = 0.007$) with an average of 92 ± 27 min from the start of OST. In the healthy group geometric means (95 % CI) for insulin were 222 (172–288) ng/L and 206 (159–267) ng/L at the 60 and 90 min sampling respectively.

**Breed comparison**

There was no effect of breed on AUCGLU, AUCINS, PeakINS, ISICOMP and T-peakINS in the group of healthy horses (Table 3).

**Repeatability testing**

The AUCGLU, AUCINS, PeakINS, ISICOMP and T-peakINS did not significantly differ between repeated tests performed in the group of healthy horses (Table 4). Among the variables derived from the OST, the AUCGLU had the best combination of repeatability measures i.e., a low mean CV, a high ICC and a relatively small RC. In contrast, PeakINS and T-peakINS had higher mean CVs as well as larger RC in relation to each of the means. Further, the PeakINS had a similar ICC as AUCGLU whilst T-peakINS had the lowest ICC of all calculated variables.

**Discussion**

A modified OST test was developed and evaluated using a Scandinavian commercially available glucose syrup (Dan Sukker Glykossirap). Higher OST glucose and insulin plasma concentrations and accordingly lower ISICOMP as well as higher AUCGLU, AUCINS and PeakINS were found in the EMS group compared to the healthy group. Moreover, the calculated parameters from the OST had moderate to high repeatability and there was no effect of breed on the test results. These results show that the modified OST appears to be a practical and useful diagnostic tool for assessment of dysinsulinemia in the horse.

It has been suggested that the OGTT and OST more closely mimic the glucose and insulin dynamics during
Fig. 1  Plasma glucose (a) and plasma insulin (b) concentrations measured during the OST in healthy (n = 23) and EMS (n = 20) groups. Data are presented as mean ± SD for plasma glucose and as geometric mean, 95% confidence interval for plasma insulin. *Groups differ at P < 0.0001. #Groups differ at P < 0.0036. OST oral sugar test; EMS equine metabolic syndrome; SD standard deviation

Fig. 2  AUC<sub>GLU</sub> (a), AUC<sub>INS</sub> (b), Peak<sub>INS</sub> (c) and ISICOMP (d) values for OST performed in healthy (n = 23) and EMS (n = 20) groups. Horizontal lines present mean, SD for AUC<sub>GLU</sub> and geometric mean, 95% confidence interval for AUC<sub>INS</sub>, Peak<sub>INS</sub> and ISICOMP. P < 0.05 represents statistical differences. OST oral sugar test; AUC<sub>GLU</sub> area under the curve for glucose; AUC<sub>INS</sub> area under the curve for insulin; Peak<sub>INS</sub> peak concentration for insulin; ISICOMP composite whole-body insulin sensitivity index; EMS, equine metabolic syndrome; SD standard deviation
physiological conditions than the EHC and the frequently sampled IV glucose tolerance test (FSIGTT). However, it is important to recognize that glucose and insulin responses after oral glucose delivery are not equivalent to insulin sensitivity. The glucose and insulin response after oral administration of glucose are dependent on factors such as gastric emptying, absorption, glucose uptake in the liver, incretin effects, insulin secretion and clearance as well as insulin sensitivity [12]. Thus, the OGTT and OST provide information about the efficiency of the homeostatic mechanisms including insulin-dependent mechanisms to restore blood glucose concentration to basal levels but not IS/IR per se. Nevertheless, several studies in humans, but also in the horse, have used different surrogate indices based on dynamic data from OGTT in order to estimate IS [8–11]. The most commonly used index in humans, ISI\textsubscript{COMP}, reflects a composite estimate of both hepatic and peripheral insulin sensitivity based on fasting glucose and insulin data as well as the mean of glucose and insulin values obtained during the OGTT. The square-root conversion in the formula is used to correct for non-linear distribution of data in relation to the IS determined by the EHC [10]. Studies in humans and horses have shown that ISI\textsubscript{COMP} has a relatively good linear correlation to quantitative measurements of IS obtained by the EHC and the surrogate index therefore provides a reasonable estimate of IS [10, 11]. Compensatory hyperinsulinemia can develop in horses with IR [21, 22] by two mechanisms: increased insulin secretion from the $\beta$-cells in the pancreas and reduced insulin clearance by the liver [21, 23–26]. This hyperinsulinemia is more pronounced and thereby easier to detect after feed intake compared to pre-prandial conditions [27, 28]. The OST is a dynamic test that mimics a feeding situation and makes it possible to study postprandial hyperinsulinemia under controlled conditions. In the present study horses in the EMS group had higher plasma insulin concentrations at all time points during the OST compared to the healthy group. The higher insulin response in the EMS group resulted in higher AUC\textsubscript{INS}, Peak\textsubscript{INS} and lower ISI\textsubscript{COMP} compared to the healthy group. In contrast, plasma glucose concentrations only differed between the healthy and the EMS group at 120, 150 and 180 min. Repeated blood sampling is necessary for calculation of AUC\textsubscript{GLU}, AUC\textsubscript{INS} and ISI\textsubscript{COMP}, making these parameters less useful during field conditions. Instead, Peak\textsubscript{INS} requires only a single sample, which reduces the costs for laboratory analyses as well as the time spent on sampling in the field during the test.

### Table 3 Calculated variables and measures for the oral sugar test (OST) in healthy Shetland ponies (n = 7), Icelandic horses (n = 8) and Standardbred horses (n = 8)

|                        | Shetland ponies | Icelandic horses | Standardbred horses | P value |
|------------------------|-----------------|------------------|---------------------|---------|
| AUC\textsubscript{GLU} (mmol/L × min) | 1071 ± 136 | 1239 ± 167 | 1100 ± 96 | 0.055 |
| AUC\textsubscript{INS} (ng/L × min)   | 32,235 ± 14,797 | 29,130 ± 14,655 | 26,967 ± 7600 | 0.728 |
| ISI\textsubscript{COMP}                | 2.2 (1.5–3.2) | 2.6 (1.8–3.7) | 2.8 (1.9–4.0) | 0.608 |
| Peak\textsubscript{INS} (ng/L)         | 301 (203–446) | 237 (164–342) | 259 (179–374) | 0.652 |
| T-peak\textsubscript{INS} (min)        | 56 ± 27 | 75 ± 23 | 75 ± 23 | 0.234 |

Data are presented as mean ± SD for AUC\textsubscript{GLU} and AUC\textsubscript{INS} and as geometric mean (95% confidence interval) for Peak\textsubscript{INS} and ISI\textsubscript{COMP}.

AUC\textsubscript{GLU} area under the curve for glucose; AUC\textsubscript{INS} area under the curve for insulin; ISI\textsubscript{COMP} composite whole-body insulin sensitivity index; Peak\textsubscript{INS} peak concentration for insulin; T-peak\textsubscript{INS} time to peak concentration for insulin; SD standard deviation.

### Table 4 Calculated variables and measures of repeatability for the oral sugar test (OST) in 15 healthy horses (7 Shetland ponies, 8 Icelandic horses)

|                        | Test 1 | Test 2 | P value | Mean CV (%) | ICC | RC |
|------------------------|--------|--------|---------|-------------|-----|-----|
| AUC\textsubscript{GLU} (mmol/L × min) | 1161 ± 171 | 1153 ± 116 | 0.823 | 6.7 | 0.79 | 237.7 |
| AUC\textsubscript{INS} (ng/L × min)   | 30,579 ± 14,276 | 31,706 ± 15,526 | 0.623 | 16.9 | 0.91 | 16,556.4 |
| ISI\textsubscript{COMP}                | 2.7 ± 1.5 | 2.8 ± 1.6 | 0.912 | 17.3 | 0.85 | 2.1 |
| Peak\textsubscript{INS} (ng/L)         | 309 ± 190 | 308 ± 153 | 0.976 | 18.3 | 0.83 | 255.5 |
| T-peak\textsubscript{INS} (min)        | 66 ± 26 | 74 ± 34 | 0.334 | 18.5 | 0.64 | 60.7 |

Data are presented as mean ± standard deviation (SD).

AUC\textsubscript{GLU} area under the curve for glucose; AUC\textsubscript{INS} area under the curve for insulin; ISI\textsubscript{COMP} composite whole-body insulin sensitivity index; Peak\textsubscript{INS} peak concentration for insulin; T-peak\textsubscript{INS} time to peak concentration for insulin; mean CV mean coefficient of variation; ICC intraclass correlation coefficient; RC repeatability coefficient.
For the USA-developed OST [14] researchers found that peak concentrations for insulin was recorded at blood sampling at 60 or 90 min after syrup administration. Hence, the time interval between 60 and 90 min after sugar administration is recommended for single blood sampling for measurements of peak insulin concentrations. In the present study, there was a longer mean time to peak insulin in the EMS group (92 ± 27 min) compared to the healthy group (69 ± 25 min). Nevertheless, plasma insulin concentration differed between the healthy and the EMS group at all time points during the OST and there was no overlap of confidence intervals. This suggests that the time frame for single blood sampling could be extended, making the test protocol more time flexible. The largest difference in plasma insulin concentrations between the two groups of horses occurred at sampling times between 60 and 150 min. However, the majority of horses included in the EMS group of the present study had a severe IR, as determined by the EHC. Severe IR is associated with a pronounced compensatory β-cell response as well as decrease in insulin clearance [22, 25], leading to a prolonged insulin response during the OST. On the other hand, a horse in an early stage of disease with a mild to moderate degree of IR, is likely to have a shorter and less prominent insulin response. Thus, if a blood sample is taken later during the OST in these horses (for example at 150 min) the insulin concentration may then have decreased to a level seen in a normal horse. The most optimal time point for sampling in order to distinguish normal horses from those with insulin dysregulation, can therefore not be concluded from the present study since it would have required a larger number of horses with a wider range of IR and β-cell responses.

The Karo® Light Corn Syrup is not available in Scandinavian grocery stores wherefore the agreement between the USA-developed OST and the modified OST could not be assessed. For the modified OST a dose of 0.2 ml/kg syrup is used, providing 216 mg saccharides/kg of body weight compared to 0.15 ml/kg of syrup for the USA developed OST that is estimated to provide the horse with 150 mg/kg of body weight of dextrose-derived digestible sugars. The total dose of sugar is thereby 44 % higher for the modified test. The glucose and insulin response after administration of syrup is not only influenced by the total amount of sugar but also the relative composition of the different sugar types. Information about the composition of the Karo® Light Corn Syrup is withheld by the manufacturer, which therefore makes it difficult to design an identical test for the Scandinavian market. Another aspect that further complicates comparisons between the two tests is that different assays have been used for measurement of plasma insulin (Coat-A-Count Insulin RIA vs Mercodia Equine Insulin ELISA).

Earlier performed work [19] showed that results were in good agreement between these two assays for samples with equine insulin concentrations <150 µU/ml, but for samples with higher insulin concentrations the agreement between assays was poor [29]. The calculated conversion factor for equine insulin from mU/L, determined with the radioimmunoassay (RIA) method, to the quantitative unit ng/L, determined with the equine specific ELISA is 10 [19]. The cutoff for dysinsulinemia for the USA developed OST is >60 mU/L (measured by the RIA) at sampling at 60–90 min [30, 31], corresponding to >600 ng/L for insulin concentrations measured by the equine ELISA. In the present study, 21 of the 23 horses in the healthy group had plasma insulin concentrations <400 ng/L at the 60 min sampling and at the 90 min sampling all healthy horses had plasma insulin concentrations <400 ng/L. In the EMS group 19 of 20 horses had plasma insulin concentrations >600 ng/L at 60 and 90 min. If the same sampling interval is used for the modified OST as for the USA developed OST (i.e. 60–90 min) it seems reasonable to use the same cut off values for the two tests.

No differences were found between breeds for any of the OST calculated variables (AUCGLU, AUCINS, ISICOMP, PeakINS and T-peakINS). Previous studies have shown differences in IS between healthy horses of different breeds using other diagnostic tests such as the CGIT [32] or the FSIGTT [28]. A small sample in combination with a relatively large within breed variation could possibly explain why no effect of breed was found in the present study. Another aspect is that only the Icelandic horses were exercised and used for leisure riding whereas the remainder (Shetland ponies and Standardbred horses) were sedentary horses. Since exercise can affect the degree of IS [33, 34], it is possible that the outcome would have been different if the degree of activity had been similar between breeds. Another explanation might be that the test is not sensitive enough to detect small differences in IS between different breed populations.

One limitation of the present study is that one group of horses (the EMS group) was tested during hospitalization whereas all other horses were tested in their home environment. In a previous study [35] no effect of housing and diet on results from the OST were found. The EMS horses in our study were acclimatized 48 h prior to testing at the large animal clinic and horses were only fed their own hay or haylage in order to minimize the possible effect of housing and feeding. Another limitation is that normal IS evaluated by EHC was not used as inclusion criteria for the healthy group. Whereas the IS of the Standardbred horses is known to be normal based on information from previous research projects where the horses’ IS have been quantified (data
not shown), the IS of the privately owned control horses is unknown. However, all control horses had normal fasting plasma insulin and glucose concentrations suggesting normal IS.

The definition of general obesity has varied among studies, e.g., BCS > 6 [5], BCS ≥ 7 [23, 36], BCS ≥ 8 [16]. Another study suggested BCS 7–7.5 as overweight but not obese [16]. The Henneke score [15] is originally adapted for use in Quarter Horses but there are no studies evaluating how well this scoring system agrees between different breeds. In addition, there seems to be breed variations as well as seasonal variations in CNS [37]. There is thus no consensus on how overweight or abnormal local adiposity should be defined for different breeds of horses. It is possible that the inclusion criteria for BCS and CNS among the normal horses in the present study should have used a narrower range. To test the hypothesis that BCS or CNS among the normal horses were associated with fasting insulin concentrations, PeakINS or ISICOMP linear regressions were performed. These regression models showed no significant correlations (P > 0.160, data not shown) suggesting no effect of BCS or CNS on the insulin response or estimates for IS in the normal horses.

The CV values for repeated tests in the present study varied between 6.7 and 18.5 % for calculated variables, where AUCGLU showed the lowest variation between tests. Higher intra-assay variability was found for analysis of insulin than for glucose in the present study, possibly affecting the CV values for the calculated parameters. In comparison, a previous study [14] using the USA developed OST, reported a similar CV for AUCGLU (6.4 %) but a higher CV for the AUCINS (45.1 %). One reason for the discrepancy of results is that fewer horses were used for repeatability testing in the aforementioned study. The insulin derived variables from the modified OST were generally considered to have a moderate to high repeatability based on CV, ICC and RC. Thus, repeatability of the OST appears to be comparable to the calculated variables from the insulin curve of another non-quantitative dynamic tests, the CGIT [32].

**Conclusions**

The results of the present study demonstrate that the modified OST appears to be a practical and useful diagnostic tool for assessment of dysinsulinemia in the horse. However, to make it possible to establish the most appropriate sampling interval and to evaluate the accuracy of the modified OST, further studies in horses with a variable degree of insulin resistance are needed, where results from the modified OST are compared with quantitative measurements for IS.

**Abbreviations**

- AUCCINS: area under the curve for insulin during OST; AUCCOMP: area under the curve for glucose during OST; BCS: body condition score; CNS: cresty neck score; CV: coefficient of variation; EHC: euglycemic hyperinsulinemic clamp; EMS: equine metabolic syndrome; FSIGTT: frequently sampled IV glucose tolerance test; ICC: intraclass correlation coefficient; IS: insulin sensitivity; ISICOMP: composite whole-body insulin sensitivity index; IR: insulin resistance; M/I60: mean rate of glucose disposal per unit of insulin during the last 60 min; OGGT: oral glucose tolerance test; OST: oral sugar test; PeakINS: peak concentration of insulin during OST; RC: repeatability coefficient; SD: standard deviation; T-peakINS: time (min) to peak concentration for insulin during OST.

**Authors’ contributions**

All authors participated in the design of the study and in the collection of the data. SL interpreted the data and performed the statistical analysis in cooperation with JB. SL drafted the manuscript, but all authors have contributed substantially to the final manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

A special thanks to all of the horse owners and to Dr. Ida Askerfelt.

**Competing interests**

None of the authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the article.

**About this supplement**

This article has been published as part of *Acta Veterinaria Scandinavica* Volume 58 Supplement 1 2016: Animal Obesity—causes, consequences and comparative aspects: current research. The full contents of the supplement are available online at http://www.actavetscand.biomedcentral.com/articles/supplements/volume-58-supplement-1.

**Availability of data and materials**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The study was approved by the Ethical Committee for Animal Experiments, Uppsala, Sweden.

**Funding**

Publication charges for this article were funded by the research platform Future Animal Health and Welfare at the Swedish University of Agricultural Sciences.

**Published:** 20 October 2016

**References**

1. Frank N, Geor R, Bailey S, Durham A, Johnson P. Equine metabolic syndrome. J Vet Intern Med. 2010;24:467–75.
2. Bailey SR, Habershon-Butcher JL, Ransom KJ, Elliott J, Menzies-Gow NJ. Hypertension and insulin resistance in a mixed-breed population of ponies predisposed to laminitis. Am J Vet Res. 2008;69:122–9.
3. Geor RJ. Metabolic predispositions to laminitis in horses and ponies: obesity, insulin resistance and metabolic syndromes. J Equine Vet Sci. 2008;28:753–9.
4. Carter RA, Treiber K, Geor R, Douglass L, Harris PA. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies. Equine Vet J. 2009;41:171–8.
5. Treiber KH, Kronfeld DS, Hess TM, Byrd BM, Splan RK, Stanier WB. Evaluation of genetic and metabolic predispositions and nutritional risk factors for pasture-associated laminitis in ponies. J Am Vet Med Assoc. 2006;228:1538–45.
6. Treiber KH, Kronfeld DS, Geor RJ. Insulin resistance in equids: possible role in laminitis. J Nutr. 2006;136:20945–85.

7. Geor RJ. Current concepts on the pathophysiology of pasture-associated laminitis. Vet Clin North Am Equine Prac. 2010;26:265–76.

8. Sturmoll M, Mitrakou A, Pimenta W, Jenssen T, Yi-Jarvinen H, Van Haeflen T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diab Care. 2000;23:295–301.

9. Gut M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, et al. Validation of the insulin sensitivity index (IS0,120): comparison with other measures. Diab Res Clin Prict. 2000;47:177–84.

10. Matsuda M, DeFiorzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab Care. 1999;22:1462–70.

11. Pratt-Phillips SE, Geor RJ, McCutcheon LJ. Comparison among the euglycemic-hyperinsulinemic clamp, insulin-modified frequently sampled intravenous glucose tolerance test, and oral glucose tolerance test for assessment of insulin sensitivity in healthy Standardbreds. Am J Vet Res. 2015;76:84–91.

12. Kronfeld DS, Treiber KH, Geor RJ. Comparison of nonspecific indications and quantitative methods for the assessment of insulin resistance in horses and ponies. J Am Vet Med Assoc. 2005;226:712–9.

13. Asplin KE, Silrence MN, Poiltt CC, McGowin CM. Induction of laminitis by prolonged hyperinsulinemia in clinically normal ponies. Vet J. 2007;174:530–5.

14. Schuver A, Frank N, Chameroy KA, Elliott SB. Assessment of insulin and glucose dynamics by using an oral sugar test in horses. J Equine Vet Sci. 2013;34:465–70.

15. Henneke D, Potter G, Kreider J, Yeates B. Relationship between condition score, physical measurements and body fat percentage in mares. Equine Vet J. 1983;15:371–2.

16. Carter RA, Geor RJ, Burton Staniar W, Cubitt TA, Harris PA. Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies. Vet J. 2009;179:204–10.

17. Lindåse SS, Nostell KE, Müller CE, Jensen-Waern M, Brojer JT. Effects of diet-induced weight gain and pasture turnout on insulin sensitivity in moderately insulin resistant horses. Am J Vet Res. 2016;77:300–9.

18. Fishman AM, Valberg SJ, Baird JD, Hunt L, DeMauro S. Insulin sensitivity in Belgian horses with polysaccharide storage myopathy. Am J Vet Res. 2008;69:818–23.

19. Ogren F, Prjører J, Wattie O, Lillehøk I. Evaluation of an equine-optimized enzyme-linked immunosorbent assay for serum insulin measurement and stability study of equine serum insulin. Comp Clin Pathol. 2012;21:1291–300.

20. Bland M. An introduction to medical statistics. 3rd ed. New York: Oxford University Press, 2000. p. 269–72.

21. Carter RA, McCutcheon LJ, George LA, Smith TL, Frank N, Geor RJ. Effects of diet-induced weight gain on insulin sensitivity and plasma hormone and lipid concentrations in horses. Am J Vet Res. 2009;70:1250–8.

22. Toth F, Frank N, Martin-Jimenez T, Elliott SB, Geor RJ, Boston RC. Measurement of C-peptide concentrations and responses to somatostatin, glucose infusion, and insulin resistance in horses. Equine Vet J. 2010;42:149–55.

23. Hoffman R, Boston R, Stefanovski D, Kronfeld D, Harris P. Obesity and diet affect glucose dynamics and insulin sensitivity in Thoroughbred geldings. J Anim Sci. 2003;81:2333–42.

24. Erdmann J, Kalabib B, Omp I, Sypchenko O, Wagengel S, Schusdziarra V. Development of hyperinsulinemia and insulin resistance during the early stage of weight gain. Am J Physiol Endocrinol Metab. 2008;294:E568–75.

25. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, et al. Longitudinal compensation for reduced insulin clearance and enhanced beta-cell response. Diabetes. 2000;49:716–25.

26. Ader M, Stefanovski D, Kim SP, Richey JM, Ionut V, Catalano KJ, et al. Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog. Obesity (Silver Spring). 2014;22:1238–45.

27. Borgia L, Valberg S, McCue M, Watts K, Pagan J. Glycaemic and insulinemic responses to feeding hay with different non-structural carbohydrate content in control and polysaccharide storage myopathy-affected horses. J Anim Physiol Anim Nutr (Berl). 2011;95:798–807.

28. Bamford JD, Potter SJ, Harris PA, Bailey SR. Breed differences in insulin sensitivity and insulimetic responses to oral glucose in horses and ponies of moderate body condition score. Domest Anim Endocrinol. 2014;47:101–7.

29. Borer-Weer KE, Bailey SR, Menzies-Gow NJ, Harris PA, Elliott J. Evaluation of a commercially available radioimmunoassay and species-specific ELISAs for measurement of high concentrations of insulin in equine serum. Am J Vet Res. 2012;73:1596–602.

30. Tadros EM, Frank N. Endocrine disorders and laminitis. Equine Vet Educ. 2013;25:152–62.

31. Frank N. Equine metabolic syndrome. Vet Clin North Am Equine Prac. 2011;27:73–92.

32. Brojer J, Lindåse S, Hedenskog L, Alvarsson K, Nostell K. Repeatability of the combined glucose-insulin tolerance test and the effect of a stressor before testing in horses of 2 breeds. J Vet Intern Med. 2013;27:1543–50.

33. Pratt S, Geor R, McCutcheon L. Effects of dietary energy source and physical conditioning on insulin sensitivity and glucose tolerance in Standardbred horses. Equine Vet J. 2006;38:579–84.

34. Steward-Hunt L, Geor R, McCutcheon L. Effects of short-term training on insulin sensitivity and skeletal muscle glucose metabolism in Standardbred horses. Equine Vet J. 2006;38:226–32.

35. Banse HE, McFarlane D. Comparison of three methods for evaluation of equine insulin regulation in horses of varied body condition score. J Equine Vet Sci. 2014;34:742–8.

36. Frank N, Elliott SB, Brandt LE, Kessler DH. Physical characteristics, blood hormone concentrations, and plasma lipid concentrations in obese horses with insulin resistance. J Am Vet Med Assoc. 2006;228:1383–90.

37. Giles SL, Nicol CJ, Rands SA, Harris PA. Assessing the seasonal prevalence and risk factors for nuchal crest adiposity in domestic horses and ponies using the cresty neck score. BMC Vet Res. 2015;11:13.